To date, there are no therapeutic strategies to correct or treat the retinal degeneration caused by mutations in CERKL. However, gene therapy for CERKL using adeno-associated viral (AAV) vectors is a possibility due to a combination of the recessive nature of the disease and small coding sequence at 1599 base pairs, which is easily encodable by adeno-associated viral (AAV) vectors similar to Luxturna, which is approved for Leber’s Congenital Amaurosis (LCA) type II. Here, CERKL is linked to retinal degeneration.